$24.73
1.035[4.37%]
At close: Apr 26
$24.73
0[0.00%]
After Hours: 4:20PM EDT
Dyne Therapeutics: Insider buying and selling updated today.
Filing Date | Insider Names | Insider Title | Qty. | Price | Size ($) | Type | Δ Own | Own | Trade Dates | SEC Filing |
---|---|---|---|---|---|---|---|---|---|---|
Mar 13, 2024 | GATTI SUSANNA HIGH | CHIEF OPERATING OFFICER | -29.491K | $26.59 | -$784.25K | SELL | -15.83% | 156.8K | Mar 08 - Mar 11 | View |
Mar 13, 2024 | Jonathan McNeill | CHIEF BUSINESS OFFICER | -1.776K | $15.82 | -$2.26M | SELL | -1.26% | 139.408K | Mar 08 - Mar 11 | View |
Mar 12, 2024 | Wildon Farwell | CHIEF MEDICAL OFFICER | -2.615K | $25.65 | -$67.08K | SELL | -1.71% | 150.56K | Mar 11 - Mar 12 | View |
Mar 12, 2024 | Richard Scalzo | SVP, HEAD FINANCE & ADMIN. | -2.672K | $15.87 | -$1.85M | SELL | -2.19% | 119.283K | Mar 08 - Mar 11 | View |
Mar 12, 2024 | Joshua Brumm | CEO & PRESIDENT | -16.387K | $15.72 | -$8.84M | SELL | -2.96% | 537.998K | Mar 08 - Mar 11 | View |
Mar 12, 2024 | Oxana Beskrovnaya | CHIEF SCIENTIFIC OFFICER | -2.081K | $25.70 | -$53.48K | SELL | -1.35% | 152.352K | Mar 11 | View |
Mar 11, 2024 | Joshua Brumm | CEO & PRESIDENT | -9.086K | $25.85 | -$234.87K | SELL | -1.61% | 554.385K | Mar 07 | View |
Mar 11, 2024 | Oxana Beskrovnaya | CHIEF SCIENTIFIC OFFICER | -2.373K | $25.85 | -$61.34K | SELL | -1.51% | 154.433K | Mar 07 | View |
Mar 11, 2024 | GATTI SUSANNA HIGH | CHIEF OPERATING OFFICER | -1.591K | $25.85 | -$41.13K | SELL | -0.85% | 186.291K | Mar 07 | View |
Mar 11, 2024 | Wildon Farwell | CHIEF MEDICAL OFFICER | -9.921K | $25.86 | -$256.58K | SELL | -6.08% | 153.175K | Mar 07 | View |
Mar 11, 2024 | Jonathan McNeill | CHIEF BUSINESS OFFICER | -2.434K | $25.85 | -$62.92K | SELL | -1.69% | 141.184K | Mar 07 | View |
Mar 11, 2024 | Richard Scalzo | SVP, HEAD FINANCE & ADMIN. | -2.273K | $25.85 | -$58.76K | SELL | -1.83% | 121.955K | Mar 07 | View |
Mar 05, 2024 | Jason Rhodes | -46.534K | $30.05 | -$1.40M | SELL | -0.71% | 6.545479M | Mar 01 | View | |
Mar 05, 2024 | Atlas Venture Opportunity Fund I LPAtlas Venture Associates Opportunity I LPAtlas Venture Associates Opportunity I LLCAtlas Venture Opportunity Fund II LPAtlas Venture Associates Opportunity II LPAtlas Venture Associates Opportunity II LLC | 10% OWNER | -46.534K | $30.05 | -$1.40M | SELL | -5.21% | 847.388K | Mar 01 | View |
Mar 01, 2024 | Joshua Brumm | CEO & PRESIDENT | 0 | $17.25 | -$2.34M | SELL-OPTIONS | 0.00% | 563.471K | Feb 29 - Mar 01 | View |
Mar 01, 2024 | Jonathan McNeill | CHIEF BUSINESS OFFICER | 0 | $14.59 | -$791.04K | SELL-OPTIONS | 0.00% | 143.618K | Feb 29 - Mar 01 | View |
Mar 01, 2024 | Richard Scalzo | SVP, HEAD FINANCE & ADMIN. | 0 | $14.54 | -$344.17K | SELL-OPTIONS | 0.00% | 124.228K | Feb 29 - Mar 01 | View |
Feb 28, 2024 | Jason Rhodes | -807.838K | $24.30 | -$19.63M | SELL | -48.31% | 864.487K | Feb 26 - Feb 28 | View | |
Feb 28, 2024 | Atlas Venture Fund XI LPAtlas Venture Associates XI LPAtlas Venture Associates XI LLCAtlas Venture Opportunity Fund I LPAtlas Venture Associates Opportunity I LPAtlas Venture Associates Opportunity I LLCAtlas Venture Opportunity Fund II LPAtlas Venture Associates Opportunity II LPAtlas Venture Associates Opportunity II LLC | 10% OWNER | -807.838K | $24.30 | -$19.63M | SELL | -48.31% | 864.487K | Feb 26 - Feb 28 | View |
Browse insider trades on all stocks.